Michael Javaheri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael Javaheri has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Avanti Ghanekar
Genentech Inc, South San Francisco, California
1 shared publicationIvaylo Stoilov
Genentech Inc, South San Francisco, California
1 shared publicationLauren Hill
Genentech Inc, South San Francisco, California
1 shared publication
Latest Publications
- 1 February 2021
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 139 (2) , 219-223
Changes in Treatment-Naive Pigment Epithelial Detachments Associated With the Initial Anti–Vascular Endothelial Growth Factor Injection
Pigment epithelial detachment (PED) is characterized by retinal pigment epithelium separation from the Bruch membrane and can be found in 63% to 80% of eyes with neovascular age-related macular degeneration (nAMD).1-4 The HARBOR trial of ranibizumab in nAMD enrolled treatment-naive patients with subfoveal choroidal neovascularization. At baseline, 54.5% of patients had PED.5 The HARBOR trial was the largest study to our knowledge to use higher-resolution spectral-domain optical coherence tomography (OCT). The objective of this post hoc analysis was to describe changes in treatment-naive PEDs following first anti–vascular endothelial growth factor (VEGF) injection and investigate whether early response is associated with treatment needs/vision outcomes at 2 years.
- 1 February 2021
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 139 (2) , 219-223
Changes in Treatment-Naive Pigment Epithelial Detachments Associated With the Initial Anti–Vascular Endothelial Growth Factor Injection
Pigment epithelial detachment (PED) is characterized by retinal pigment epithelium separation from the Bruch membrane and can be found in 63% to 80% of eyes with neovascular age-related macular degeneration (nAMD).1-4 The HARBOR trial of ranibizumab in nAMD enrolled treatment-naive patients with subfoveal choroidal neovascularization. At baseline, 54.5% of patients had PED.5 The HARBOR trial was the largest study to our knowledge to use higher-resolution spectral-domain optical coherence tomography (OCT). The objective of this post hoc analysis was to describe changes in treatment-naive PEDs following first anti–vascular endothelial growth factor (VEGF) injection and investigate whether early response is associated with treatment needs/vision outcomes at 2 years.